BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3243041)

  • 21. Treatment of vasculitic IgA nephropathy.
    Harper L; Ferreira MA; Howie AJ; Savage CO; Richards NT; Michael J; Adu D
    J Nephrol; 2000; 13(5):360-6. PubMed ID: 11063140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study.
    Hotta O; Taguma Y; Kurosawa K; Sudo K; Suzuki K; Horigome I
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):967-73. PubMed ID: 8255008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prognosis and treatment of membranous glomerulonephritis-a 5-year prospective study].
    Covic A; Căruntu ID; Marian D; Volovăţ C; Ghiciuc C; Costin C; Florea L; Cotuţiu C; Covic M
    Rev Med Chir Soc Med Nat Iasi; 2000; 104(2):63-74. PubMed ID: 12089993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure.
    Warwick GL; Geddes CG; Boulton-Jones JM
    Q J Med; 1994 Apr; 87(4):223-9. PubMed ID: 8208913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment and long-term follow-up of patients with stage II to III idiopathic membranous nephropathy.
    Polenakovik MH; Grcevska L
    Am J Kidney Dis; 1999 Nov; 34(5):911-7. PubMed ID: 10561149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
    Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
    Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions.
    Faedda R; Pirisi M; Satta A; Tanda F; Bartoli E
    Clin Nephrol; 1996 Oct; 46(4):237-44. PubMed ID: 8905208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
    Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
    Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.
    Ponticelli C; Passerini P; Salvadori M; Manno C; Viola BF; Pasquali S; Mandolfo S; Messa P
    Am J Kidney Dis; 2006 Feb; 47(2):233-40. PubMed ID: 16431252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis?
    Davenport A; Maciver AG; Hall CL; MacKenzie JC
    Clin Nephrol; 1994 May; 41(5):271-6. PubMed ID: 8050206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
    Woo KT; Edmondson RP; Yap HK; Wu AY; Chiang GS; Lee EJ; Pwee HS; Lim CH
    Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of steroid therapy in different stages of membranous nephropathy.
    Fuiano G; Stanziale P; Balletta M; Sepe V; Marinelli G; Comi N; Esposito A; Andreucci VE
    Nephrol Dial Transplant; 1989; 4(12):1022-9. PubMed ID: 2517322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
    Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
    J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
    Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
    Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idiopathic membranous nephropathy in the elderly.
    Passerini P; Como G; Viganò E; Melis P; Pozzi C; Altieri P; Ponticelli C
    Nephrol Dial Transplant; 1993; 8(12):1321-5. PubMed ID: 8159299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of Japanese membranous nephropathy patients with nephrotic syndrome.
    Nishi S; Ueno M; Shimada H; Karasawa R; Nakamaru T; Miyakawa Y; Arakawa M
    Kidney Int Suppl; 1997 Dec; 63():S177-8. PubMed ID: 9407452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membranous nephropathy: a 19 year prospective study in 51 patients.
    Hay NM; Bailey RR; Lynn KL; Robson RA
    N Z Med J; 1992 Dec; 105(947):489-91. PubMed ID: 1461605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects.
    Terrier B; Delmas Y; Hummel A; Presne C; Glowacki F; Knebelmann B; Combe C; Lesavre P; Maillard N; Noël LH; Patey-Mariaud de Serre N; Nusbaum S; Radford I; Buzyn A; Fakhouri F
    Nephrol Dial Transplant; 2007 May; 22(5):1369-76. PubMed ID: 17255123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.